Mustang Bio announces a 1-for-50 reverse stock split to comply with Nasdaq listing requirements, effective January 16, 2025. Mustang Bio, Inc. has announced a 1-for-50 reverse stock split of its ...
Clinical-stage biotech firm Mustang Bio (NASDAQ:MBIO) stock rallied 180% on Monday to £2.46 ($3.34) per share after the US Food and Drug Administration granted Orphan Drug Designation to its MB-101 ...
WORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical ...
In a stark reflection of investor sentiment, Mustang Bio (NASDAQ:MBIO) Inc.'s stock has tumbled to a 52-week low, touching down at $2.6, a dramatic fall from its 52-week high of $74.5. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results